Clinical innovation of glucose-containing dialysate: transition from osmotic regulation to multisystem regulation_West China Medical Journal

Authors：

ZHOU Zhifeng ,  ZHANG Ling

Department of Nephrology and Institute of Kidney Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

ZHANG Ling, Email: zhangling_crrt@163.com

Keywords：

Hemodialysis; glucose-containing dialysate; multisystem regulation; glucose regulation; blood regulation

DOI：

10.7507/1002-0179.202506139

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Hemodialysis, serving as a crucial renal replacement therapy for patients with end-stage kidney disease, has consistently prioritized the optimization of dialysate composition in clinical practice. The application of glucose-containing dialysate has undergone a conceptual evolution from its initial role in osmotic regulation to its current recognition as a multifunctional systemic modulator. Accumulating evidence demonstrates that glucose-containing dialysate exhibits distinctive clinical advantages in maintaining glycemic and hemodynamic stability while reducing heart rate variability among hemodialysis patients. Nevertheless, existing studies present certain limitations, including relatively small sample sizes and insufficient evaluation of long-term prognostic indicators. Consequently, future investigations should emphasize large-scale, multicenter clinical trials with extended follow-up periods to further substantiate the therapeutic benefits of glucose-containing dialysate in clinical practice.

Citation： ZHOU Zhifeng, ZHANG Ling. Clinical innovation of glucose-containing dialysate: transition from osmotic regulation to multisystem regulation. West China Medical Journal, 2025, 40(7): 1034-1037. doi: 10.7507/1002-0179.202506139 Copy

1.	GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2020, 395(10225): 709-733.
2.	Sharma R, Rosner MH. Glucose in the dialysate: historical perspective and possible implications?. Hemodial Int, 2008, 12(2): 221-226.
3.	Cui L, Meng Y, Xu D, et al. Analysis of the metabolic properties of maintenance hemodialysis patients with glucose-added dialysis based on high performance liquid chromatography quadrupole time-of-flight mass spectrometry. Ther Clin Risk Manag, 2013, 9: 417-425.
4.	Yu TM, Lin CL, Chang SN, et al. Increased risk of stroke in patients with chronic kidney disease after recurrent hypoglycemia. Neurology, 2014, 83(8): 686-694.
5.	孫艷君. 含糖透析液對糖尿病透析患者透析低血糖和低血壓的影響. 糖尿病新世界, 2017, 20(15): 37-38.
6.	韓雨, 曲志杰, 封文媛, 等. 維持性血液透析患者透析中血糖變化及低血糖發生情況分析. 中國血液凈化, 2023, 22(6): 421-425.
7.	牙秋艷, 陳柱, 黃柳慧, 等. 含糖透析液在老年非糖尿病維持性透析患者中應用的有效性和安全性分析. 大醫生, 2024, 9(11): 74-76.
8.	黎小燕, 楊光, 鐘樹妹. 老年終末期糖尿病腎病血透使用含糖透析液對低血糖及低血壓發生率的影響. 中外醫學研究, 2013(18): 18-19.
9.	張守清. 含糖或無糖透析液對糖尿病腎病血液透析患者平均動脈壓和心率變異性的影響. 實用心腦肺血管病雜志, 2014(7): 73-74.
10.	李俠, 趙新菊, 曹立云, 等. 含糖透析液對維持性血液透析患者心率變異性和血壓的影響. 中國血液凈化, 2010, 9(3): 138-142.
11.	Raimann JG, Kruse A, Thijssen S, et al. Metabolic effects of dialyzate glucose in chronic hemodialysis: results from a prospective, randomized crossover trial. Nephrol Dial Transplant, 2012, 27(4): 1559-1568.
12.	Simic-Ogrizovic S, Backus G, Mayer A, et al. The influence of different glucose concentrations in haemodialysis solutions on metabolism and blood pressure stability in diabetic patients. Int J Artif Organs, 2001, 24(12): 863-869.
13.	Bushljetik IR, Trajceska L, Pusevski V, et al. Glucose levels during dialysis with glucose-free versus glucose-rich dialysate fluid. Pril (Makedon Akad Nauk Umet Odd Med Nauki), 2019, 40(3): 41-46.
14.	Iatridi F, Theodorakopoulou MP, Karagiannidis AG, et al. Intradialytic hypertension in maintenance hemodialysis. Curr Hypertens Rep, 2024, 27(1): 1.
15.	Tislér A, Akócsi K, Borbás B, et al. The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis. Nephrol Dial Transplant, 2003, 18(12): 2601-2605.
16.	趙谷天, 楊麗萍, 陳浩. 含糖透析液對維持性血透病人血透過程中血糖和血壓水平的影響. 中外女性健康研究, 2021(13): 85-86.
17.	曹偉波. 含糖透析液對糖尿病腎病血液透析患者的影響. 中外醫療, 2017, 36(8): 25-27.
18.	王天智, 劉翠紅. 含糖透析液在糖尿病腎病維持性血液透析病人中的應用. 中國婦幼健康研究, 2016, 27(增刊 1): 272-273.
19.	Khan MS, Javaid SS, Mentz RJ, et al. Heart rate variability in patients with cardiovascular diseases. Prog Cardiovasc Dis, 2025.
20.	Padilla VJ, Scheffrahn K, Mu?iz V, et al. Heart rate variability, hypnosis, and psychotherapy. Appl Psychophysiol Biofeedback, 2025, 50(2): 289-295.
21.	任迎, 胡作祥, 單薇, 等. 含糖透析液對糖尿病腎病血液透析患者血壓和心率變異性的影響. 中國現代醫生, 2011(25): 31-33.
22.	Ferrario M, Raimann JG, Thijssen S, et al. Effects of dialysate glucose concentration on heart rate variability in chronic hemodialysis patients: results of a prospective randomized trial. Kidney Blood Press Res, 2011, 34(5): 334-343.
23.	Li M, Li Y, Lv J, et al. The effects of glucose-free and glucose-containing dialysate during dialysis in MHD patients: a prospective cross-over study. Perfusion, 2023, 38(1): 178-185.
24.	Dolegowska B, Stepniewska J, Ciechanowski K, et al. Does glucose in dialysis fluid protect erythrocytes in patients with chronic renal failure?. Blood Purif, 2007, 25(5/6): 422-429.
25.	Bober J, Kwiatkowska E, Kedzierska K, et al. Does glucose present in the dialysate limit oxidative stress in patients undergoing regular hemodialysis?. Blood Purif, 2005, 23(3): 219-225.

1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2020, 395(10225): 709-733.
2. Sharma R, Rosner MH. Glucose in the dialysate: historical perspective and possible implications?. Hemodial Int, 2008, 12(2): 221-226.
3. Cui L, Meng Y, Xu D, et al. Analysis of the metabolic properties of maintenance hemodialysis patients with glucose-added dialysis based on high performance liquid chromatography quadrupole time-of-flight mass spectrometry. Ther Clin Risk Manag, 2013, 9: 417-425.
4. Yu TM, Lin CL, Chang SN, et al. Increased risk of stroke in patients with chronic kidney disease after recurrent hypoglycemia. Neurology, 2014, 83(8): 686-694.
5. 孫艷君. 含糖透析液對糖尿病透析患者透析低血糖和低血壓的影響. 糖尿病新世界, 2017, 20(15): 37-38.
6. 韓雨, 曲志杰, 封文媛, 等. 維持性血液透析患者透析中血糖變化及低血糖發生情況分析. 中國血液凈化, 2023, 22(6): 421-425.
7. 牙秋艷, 陳柱, 黃柳慧, 等. 含糖透析液在老年非糖尿病維持性透析患者中應用的有效性和安全性分析. 大醫生, 2024, 9(11): 74-76.
8. 黎小燕, 楊光, 鐘樹妹. 老年終末期糖尿病腎病血透使用含糖透析液對低血糖及低血壓發生率的影響. 中外醫學研究, 2013(18): 18-19.
9. 張守清. 含糖或無糖透析液對糖尿病腎病血液透析患者平均動脈壓和心率變異性的影響. 實用心腦肺血管病雜志, 2014(7): 73-74.
10. 李俠, 趙新菊, 曹立云, 等. 含糖透析液對維持性血液透析患者心率變異性和血壓的影響. 中國血液凈化, 2010, 9(3): 138-142.
11. Raimann JG, Kruse A, Thijssen S, et al. Metabolic effects of dialyzate glucose in chronic hemodialysis: results from a prospective, randomized crossover trial. Nephrol Dial Transplant, 2012, 27(4): 1559-1568.
12. Simic-Ogrizovic S, Backus G, Mayer A, et al. The influence of different glucose concentrations in haemodialysis solutions on metabolism and blood pressure stability in diabetic patients. Int J Artif Organs, 2001, 24(12): 863-869.
13. Bushljetik IR, Trajceska L, Pusevski V, et al. Glucose levels during dialysis with glucose-free versus glucose-rich dialysate fluid. Pril (Makedon Akad Nauk Umet Odd Med Nauki), 2019, 40(3): 41-46.
14. Iatridi F, Theodorakopoulou MP, Karagiannidis AG, et al. Intradialytic hypertension in maintenance hemodialysis. Curr Hypertens Rep, 2024, 27(1): 1.
15. Tislér A, Akócsi K, Borbás B, et al. The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis. Nephrol Dial Transplant, 2003, 18(12): 2601-2605.
16. 趙谷天, 楊麗萍, 陳浩. 含糖透析液對維持性血透病人血透過程中血糖和血壓水平的影響. 中外女性健康研究, 2021(13): 85-86.
17. 曹偉波. 含糖透析液對糖尿病腎病血液透析患者的影響. 中外醫療, 2017, 36(8): 25-27.
18. 王天智, 劉翠紅. 含糖透析液在糖尿病腎病維持性血液透析病人中的應用. 中國婦幼健康研究, 2016, 27(增刊 1): 272-273.
19. Khan MS, Javaid SS, Mentz RJ, et al. Heart rate variability in patients with cardiovascular diseases. Prog Cardiovasc Dis, 2025.
20. Padilla VJ, Scheffrahn K, Mu?iz V, et al. Heart rate variability, hypnosis, and psychotherapy. Appl Psychophysiol Biofeedback, 2025, 50(2): 289-295.
21. 任迎, 胡作祥, 單薇, 等. 含糖透析液對糖尿病腎病血液透析患者血壓和心率變異性的影響. 中國現代醫生, 2011(25): 31-33.
22. Ferrario M, Raimann JG, Thijssen S, et al. Effects of dialysate glucose concentration on heart rate variability in chronic hemodialysis patients: results of a prospective randomized trial. Kidney Blood Press Res, 2011, 34(5): 334-343.
23. Li M, Li Y, Lv J, et al. The effects of glucose-free and glucose-containing dialysate during dialysis in MHD patients: a prospective cross-over study. Perfusion, 2023, 38(1): 178-185.
24. Dolegowska B, Stepniewska J, Ciechanowski K, et al. Does glucose in dialysis fluid protect erythrocytes in patients with chronic renal failure?. Blood Purif, 2007, 25(5/6): 422-429.
25. Bober J, Kwiatkowska E, Kedzierska K, et al. Does glucose present in the dialysate limit oxidative stress in patients undergoing regular hemodialysis?. Blood Purif, 2005, 23(3): 219-225.

Previous Article
Research advances in blood purification solutions
Next Article
Advances in the application of hemofiltration replacement fluid of sodium citrate in continuous renal replacement therapy

West China Medical Journal

Clinical innovation of glucose-containing dialysate: transition from osmotic regulation to multisystem regulation

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content